Eli Lilly (LLY)

NetworkNewsWire Editorial Coverage : The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral and intravenous treatments continue to face significant challenges, chief among them low bioavailability and inadequate tumor targeting. These factors often limit the success of these treatments in clinical settings. Breakthroughs in nanomedicine are now addressing these obstacles, with growing support from the U.S. Food and Drug Administration (“FDA”), along with other regulators for nanocarrier-based delivery technologies used in advanced therapeutics. This accelerating adoption highlights a broader shift across the industry: a race to optimize how medicines are transported, absorbed, and activated within the human body. Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( profile ) is at the forefront of this movement with its proprietary Deciparticle(TM) platform, designed to enhance both the bioavailability and therapeutic index of existing oncology drugs. By improving the performance of underutilized compounds, the technology could help redefine standards for cancer treatment. The company’s recent advancement of Sapu-003 into human trials reflects growing traction for this approach, demonstrating how next-generation delivery science can unlock new therapeutic value and reshape the future of oncology innovation. Oncotelic Therapeutics is committed to making a difference in the global oncology space, positioning itself as an innovator along with other companies working to make a difference in cancer treatment, including Iovance Biotherapeutics Inc . (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and…

As 2025 winds down, the biotechnology sector is heating up, signaling a rare window of opportunity for investors. After a period of uneven performance, the industry is regaining momentum, with the global biotech market projected to grow from $1.74 trillion in 2025 to more than $5 trillion by 2034, reflecting a robust annual growth rate of 12.5 percent.

When news broke that Johnson & Johnson was in talks to acquire Protagonist Therapeutics (NASDAQ:PTGX), the stock surged before trading was halted for volatility. Whether or not the deal closes, the signal to investors was unmistakable: peptides are back. Long viewed as hard to develop, lacking bioavailability when taken orally and more complex than biologics, they’ve proven their commercial power through GLP-1 blockbusters like Wegovy, Rybelsus and Zepbound - medicines that are now addressing a billion patients with major chronic metabolic conditions, and now dominate the multi billion dollar diabetes and weight-loss markets. In short, the advent of peptide therapeutics has been redefined.

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END

Novo Nordisk (NYSE: NVO) just put 9,000 employees on the chopping block in what it’s calling an effort to “reduce complexity.” Translation: the world’s onetime obesity drug darling is cleaning house after years of chasing growth that turned into bloat.

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ). This fund provides investors with amplified 2X inverse daily exposure to the performance of Eli Lilly and Company (NYSE: LLY), enabling retail investors to seek enhanced downside exposure without the need for a margin account.

- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer –

The obesity treatment market is exploding, with Goldman Sachs projecting it to reach $130 billion by 2030. Driven by rising global obesity rates—now at 42% of U.S. adults, per the CDC—the sector has become a magnet for investors seeking exposure to transformative medicine.

PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.

Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) may have just positioned itself as a serious contender in the rapidly expanding obesity treatment market with impressive new preclinical data for its oral MC4R agonist PL7737. The results, announced today, demonstrate both rapid weight loss as a standalone therapy and enhanced effects when combined with GLP-1 medications like tirzepatide.

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market capitalization has risen farthest? Whose

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of health-care companies to

BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:LLY),(NASDAQ:PLTR),(NYSE:PHG),(NASDAQ:WAY) EQNX::TICKER_END

BALA CYNWYD, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

JACKSONVILLE, Fla., June 17, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads announced today the May 2025 results for its new planned capital project spending report for the Industrial Manufacturing industry. The report reveals a continuation of robust activity. The Firm, which tracks North American planned industrial capital project activity including facility expansions, new plant construction, and significant equipment modernization projects, confirmed 146 new projects in the Industrial Manufacturing sector for May. - News from Industrial SalesLeads Inc, issued by Send2Press Newswire

Behind-the-scenes video captures this milestone for American solar — creating local jobs and reinforcing why federal support for clean energy matters

Ireland has emerged as the undisputed champion in attracting U.S. foreign direct investment, hosting an extraordinary €897 billion (over $1 trillion) in American capital. This massive investment flow has transformed the small island nation into America's premier European platform, with U.S. affiliate assets reaching approximately $2 trillion in 2021.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

By Meg Flippin Benzinga

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update.

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”).   The transaction was completed on March 25, 2025.